FDA investigates patient deaths after treatment with Sarepta's gene therapy
In June, Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and future demand for the treatment.
The patients who died were a 16-year-old, weighing 70 kilograms, and a 15-year-old, weighing 50 kilograms. Both boys were non-ambulatory and their deaths occurred within 90 days after treatment, the company said in an investor call last week.
The two patients showed signs of acute liver failure and were hospitalized less than two months after treatment with Elevidys, the health regulator said on Tuesday. It added that it is evaluating the need for further regulatory action.
Sarepta said in an email to Reuters, "The FDA communication was triggered by our report to the FDA and our suggested update to the label to include information relating to the recent events."
The U.S. prescribing information for Elevidys warns of acute liver injury but does not mention liver failure or death.
Elevidys, approved by the FDA in 2024 for ambulatory Duchenne muscular dystrophy patients aged four and older, is the only gene therapy available for the disease. It carries a known risk of liver damage and was conditionally approved for non-ambulatory patients despite failing to meet the main goal in a late-stage study.
Sarepta said earlier this month it was investigating both cases independently and in relation to each other to identify any common risk factors.
The company has suspended its Elevidys sales forecast for 2025, halted shipments to non-ambulatory patients and is working with regulators on a new treatment plan.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 hours ago
- USA Today
Princess Kate says life after cancer is a 'roller coaster'
Princess Kate has revealed she had to put on a "brave face" throughout and following her cancer treatment last year, describing the ordeal as a "life-changing" experience. Kate, 43, shared publicly to the shock of many in March 2024 that she would undergo a course of chemotherapy after tests taken following major abdominal surgery revealed that an unspecified form of cancer had been present, weeks after her father-in-law, King Charles III, announced his own cancer diagnosis. She completed the course of treatment in September, the princess shared in a video posted to social media at the time. In January she announced her cancer was in remission after an appearance at the hospital where she was treated. "You put on a sort of brave face, stoicism through treatment. Treatment's done, then it's like, 'I can crack on, get back to normal,' but actually the phase afterwards is really, really difficult," Kate said during a visit to Colchester Hospital in Essex, southeast England, on Wednesday, July 2. Speaking to staff, patients and volunteers at the hospital, the princess emphasized the importance of support after treatment, noting that while patients may no longer be under clinical care, they often still struggle to "function normally at home" as they once did. "And actually, someone to help talk you through that, show you and guide you through that sort of phase that comes after treatment, I think is really valuable," she added, according to People. Princess Kate opens up about cancer experience at hospital where she got treatment Kate described the cancer diagnosis and treatment as "life-changing" for both patients and their loved ones. "You have to find your new normal and that takes time … And it's a roller coaster. It's not smooth, like you expect it to be," she said, according to the outlet. "But the reality is you go through hard times." The princess has been gradually resuming her public royal role but missed the Royal Ascot horse racing event in June, with husband Prince William attending the royal procession at the horse racing event in southern England solo. Contributing: Reuters; Taijuan Moorman, USA TODAY
Yahoo
3 hours ago
- Yahoo
FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff
WASHINGTON (AP) — The government's top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday. The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. Both vaccines were approved by the FDA in May after months of analysis by rank-and-file FDA reviewers. But internal correspondence show Prasad disagreed with staffers who planned to approve the shots for everyone 12 and older, similar to previous COVID vaccines. The scientists had concluded the benefit from the vaccines and the risk of COVID-19 outweighed the risk of possible side effects, which are rare. Instead Prasad decided the shots should be limited to those who face special risks from the virus— seniors or children and adults with underlying medical issues. Prasad explained that the COVID vaccine benefits must be reconsidered in light of falling rates of death and hospitalization and the possibility for vaccine side effects. It's the latest in a series of vaccine restrictions imposed by officials working under Kennedy, who has long questioned the benefits of vaccines. 'Even rare vaccination related harms both known and unknown now have higher chance of outweighing potential benefits' Prasad wrote in a five-page memo explaining his decision. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months. Top FDA leaders are typically not involved in the review of individual products. Officials like Prasad can overrule staffers, but such cases are rare and often controversial. News of the FDA documents was first reported by the New York Times. Prasad was hired to lead the FDA's vaccine center in May, after the previous director, Dr. Peter Marks, was forced to resign over disagreements with Kennedy. An academic researcher specializing in cancer therapies, Prasad came to prominence during the pandemic for criticizing public health measures, including the FDA's approval of COVID boosters for healthy adults and children. Since arriving at the agency he has worked with FDA Commissioner Mark Makary on new guidelines that will limit approvals of future COVID boosters to higher-risk Americans, mainly seniors and those with medical conditions like asthma and obesity. Those limits match the terms FDA recently approved for Novavax's shot, Nuvaxovid and Moderna's mNexspike. Novavax's vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna's vaccine is an updated, lower-dose version of its existing mRNA-based vaccine. The review team for the Novavax vaccine pointed to data from a study in 30,000 adults, concluding that 'the risk-benefit assessment for this vaccine technology remains favorable.' FDA staff reached a similar conclusion for the Moderna vaccine, deeming it similar in safety and effectiveness to the company's original shot. Last week, the FDA finalized new warning labeling about the risk of myocarditis, a rare form of heart inflammation, on shots from Moderna and Pfizer, the other maker of an mRNA-based shot for COVID. In his 'override memo,' reversing FDA staff's decision on the Moderna shot, Prasad pointed to the ongoing risk of myocarditis and questions about its frequency. The agency ordered Moderna to conduct further studies of the risk as a condition for the approving its updated shot. A spokesman for the administration said Prasad 'has raised serious concerns' about the issue. 'We will not ignore these risks and will ensure that the gold standard of science is used for any decisions,' said Andrew Nixon, in an emailed statement. Outside researchers have noted that cases of the heart condition tend to resolve quickly and are less severe than those associated with COVID infection itself, which can also cause myocarditis. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Associated Press
4 hours ago
- Associated Press
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class antibacterial approved by the U.S. Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI), today announced that it has been acquired by Alembic Pharmaceuticals, Inc. (Alembic). PIVYA marked the first antibiotic in approximately 20 years to earn FDA approval for uUTI, a common bacterial infection that afflicts millions of women annually. The FDA approved PIVYA in April 2024 for use in female patients 18 years of age and older with uUTI caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. PIVYA has a unique mechanism of action that targets the cell wall of gram-negative bacteria. Additional U.S. prescribing information about PIVYA can be found at 'We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the U.S.,' said Tom Hadley, President and CEO of UTILITY therapeutics. 'With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides U.S. clinicians with a new and effective treatment option that has a long safety record. We are grateful for the support of our Board of Directors and investors, including the AMR Action Fund, whose collective support was instrumental in helping us obtain FDA approval for PIVYA.' The UTILITY therapeutics Ltd. Board of Directors and Observers includes: 'The acquisition of UTILITY and the commercialization of PIVYA are important steps in Alembic's strategic goal to provide branded pharmaceutical products to the U.S. healthcare market,' said Craig Salmon, President of Alembic Pharmaceuticals, Inc. 'PIVYA will further enhance Alembic's ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on specialty segments. Alembic plans to make PIVYA available in the U.S. in the 4th quarter of 2025.' 'I am excited to see Alembic drive the commercialization of PIVYA, which is uniquely positioned to help millions of American women with urinary tract infections,' said Dr. Morten Sommer, Professor of microbiology at the Technical University of Denmark, and co-founder and board member of UTILITY therapeutics. 'With a novel mechanism of action, not previously deployed in the U.S., PIVYA can become a cornerstone of the treatment of urinary tract infections based on its first-line positioning in the Infectious Disease Society of America treatment guidelines. On behalf of the co-founders, investors, and Board of Directors, we are excited that PIVYA will help address the societal impact of the uUTI disease burden in women.' About PIVYA (pivmecillinam oral tablets 185mg) PIVYA, an oral prodrug of mecillinam, is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. Mecillinam demonstrated in vitro activity against Enterobacterales in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBL) of the following groups: CTX-M, SHV, TEM, AmpC. The inhibitory action of mecillinam on PBP-2 results in low cross-resistance with certain beta-lactams. The frequency of resistance to mecillinam in E. coli range from 8×10-8 to 2×10-5 when exposed to 32-256 times MIC. PIVYA has been proven safe and effective in three clinical trials with the most common Adverse Reactions Occurring in ≥1% of Patients Receiving PIVYA (Adjusted for Study Size); Nausea (4.3%), Diarrhea (2.1%), Vulvovaginal candidiasis (1.8%), Genital pruritus (1.8%), and Headache (1.4%). PIVYA demonstrated strong response in three controlled clinical trials comparing different PIVYA dosing regimens to placebo (Trial 1), to another oral antibacterial drug (Trial 2), or to ibuprofen (Trial 4) evaluated the efficacy of pivmecillinam for the treatment of uUTI. Efficacy was assessed in the Microbiological Intent-to-Treat (micro-ITT) population which included all randomized subjects with a positive baseline urine culture defined as ≥105 colony-forming-units (CFU)/mL of a uropathogen where CFU count was available and no more than 2 species of microorganisms, regardless of colony count, and no baseline pathogen was non-susceptible to the active comparator. The composite response rates (composite endpoint of clinical cure and microbiological response), as well as clinical cure and microbiological response rates of the recommended 185 mg three times daily dosing regimen. Composite Response Rates (Clinical Cure and Microbiological Response) at TOC in the uUTI trials (Micro ITT Population) Clinical Cure Rates (Micro-ITT Population) Microbiological Response Rates (Micro-ITT Population) Contraindications Warnings and precautions About UTILITY therapeutics Ltd. UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an oral prodrug of mecillinam that has been approved by the FDA for the treatment of women with uncomplicated urinary tract infections. PIVYA has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, may be developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting. For more information, contact David Cobb, Alembic Pharmaceuticals [email protected] 908-552-583 SOURCE: Utility Therapeutics Ltd. press release
